Avidity Biosciences CSO Art Levin and CEO Sarah Boyce
December 14, 2022 11:13 AM EST
R&D

Avid­i­ty touts ear­ly da­ta, show­ing pos­i­tive ef­fect on pro­gres­sive mus­cu­lar dis­ease while un­der par­tial FDA hold

Paul Schloesser

Associate Editor

An RNA biotech is look­ing to tout Phase I/II da­ta as in­vestors sent its share price on a re­bound.

Avid­i­ty Bio­sciences said Wednes­day that its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times